MICHELLE A FANALE to Administration, Oral
This is a "connection" page, showing publications MICHELLE A FANALE has written about Administration, Oral.
Connection Strength
0.039
-
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012 Nov 20; 30(33):4161-7.
Score: 0.020
-
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec; 12(13):1222-8.
Score: 0.019